The quest for effective treatments in the fight against metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as non-alcoholic steatohepatitis (NASH), has reached an exciting new threshold. Boehringer Ingelheim has shared groundbreaking results from their Phase II clinical
In a significant expansion of its life sciences portfolio, global science and technology leader Merck has announced a definitive agreement to purchase Mirus Bio for a staggering $600 million. Mirus Bio, a pioneering life sciences company, specializes in developing transfection reagents, a
The battle against cancer is one that has engaged the global medical community for decades, and with the emergence of Chimeric Antigen Receptor (CAR) T-cell therapy, we stand on the precipice of a significant revolution in the way cancer is treated. This immunotherapy transforms a patient's own
In a significant stride for medical science, PhoreMost Ltd., a biotechnological innovator, has forged a promising path in retinal therapy through its alliance with the pharmaceutical giant Boehringer Ingelheim. The joint venture, which kicked off in January 2020, has recently celebrated a crucial
Introduction Retro Biosciences, a pioneering biotech company, has embarked on an ambitious journey to extend human lifespan by a decade through innovative approaches to combat cellular aging. Its strategic partnership with Multiply Labs, a firm celebrated for advanced automation and robotic
The relentless progress of medical technology regularly unlocks new arenas in the battle against disease, with one of the most notable being the potent capabilities of Natural Killer (NK) cell therapies. As critical members of the immune system, NK cells have become the cornerstone of an innovative
